Sodium zirconium cyclosilicate: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 61: | Line 61: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Latest revision as of 21:57, 20 March 2026
Administration[1]
- Type: Potassium binder, antidote
- Dosage Forms: 5 g (1 ea, 30 ea); 10 g (1 ea, 30 ea), empty contents into glass with 45 mL of water
- Routes of Administration: Oral
- Common Trade Names: Lokelma
Adult Dosing
Hyperkalemia
- 10 g TID PO for up to 48 hours, then 10 g once daily
Pediatric Dosing
Special Populations
Pregnancy Rating
- unlikely to affect fetus as not absorbed
Lactation risk
- unlikely to be in breast milk as not absorbed
Renal Dosing
None
Hepatic Dosing
None
Contraindications
- Allergy to class/drug
- Avoid in GI motility disorders
Adverse Reactions
Serious
Common
- Mild to moderate edema
- Hypokalemia
Pharmacology
- Metabolism: none
- Excretion: feces
Mechanism of Action
- Highly selective, oral potassium removing agent
- Non-absorbed zirconium silicate that captures potassium in exchange for hydrogen and sodium
- Increases fecal potassium excretion through binding K+ in GI tract
Comments
- Onset of action at 1.0 hour and median time to achieving normal potassium levels at 2.2 hours, with 92% achieving normal potassium within 48 hours.
- Not used as an emergency treatment for life threatening hyperkalemia due to delayed onset of action
- Available at Harbor-UCLA, but not yet widely available in the community
- If asked by nephrology to give Kayexalate, kindly suggest Lokelma instead
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
See Also
References
- ↑ Packham, D. K., Rasmussen, H. S., Lavin, P. T., El-Shahawy, M. A., Roger, S. D., Block, G., … Singh, B. (2015). Sodium zirconium cyclosilicate in hyperkalemia. The New England Journal of Medicine, 372(3), 222–231.